Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Interferon-beta in pediatric multiple sclerosis patients: safety in short-term prescription.
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Epigenetic Modulation of Human Induced Pluripotent Stem Cell Differentiation to Oligodendrocytes.
Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies.
A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci.
A comparison of phase imaging and quantitative susceptibility mapping in the imaging of multiple sclerosis lesions at ultrahigh field.
Information for healthcare professionals: Rituximab
Dimethylfumarate protects against TNF-α-induced secretion of inflammatory cytokines in human endothelial cells.
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
NOVANTRONE. mitoXANTRONE for injection concentrate
Identical lesion morphology in primary progressive and relapsing-remitting MS -an ultrahigh field MRI study.
An Exploratory Investigation of Social Stigma and Concealment in Patients with Multiple Sclerosis.
IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.
Clinical experience with repository corticotropin injection in patients with multiple sclerosis experiencing mood changes with intravenous methylprednisolone: a case series.
Studying both sexes: a guiding principle for biomedicine.
A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.
U.S. Patent Office Declares an Interference Between Forward Pharma and Biogen Regarding the Treatment of Multiple Sclerosis With 480 mg Daily Dose of DMF, the Active Ingredient in Tecfidera(R)
Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders.
Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience.
Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders.
Ampyra (dalfampridine)
Comparative miRNA-Based Fingerprinting Reveals Biological Differences in Human Olfactory Mucosa- and Bone-Marrow-Derived Mesenchymal Stromal Cells.
Charcot-Marie-Tooth 1A: a narrative review with clinical and anatomical perspectives.
Multiple sclerosis: clinical presentation, diagnosis and treatment.

Pages